Cargando…
A Role for Xanthurenic Acid in the Control of Brain Dopaminergic Activity
Xanthurenic acid (XA) is a metabolite of the kynurenine pathway (KP) synthetized in the brain from dietary or microbial tryptophan that crosses the blood-brain barrier through carrier-mediated transport. XA and kynurenic acid (KYNA) are two structurally related compounds of KP occurring at micromola...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268472/ https://www.ncbi.nlm.nih.gov/pubmed/34203531 http://dx.doi.org/10.3390/ijms22136974 |
_version_ | 1783720365499875328 |
---|---|
author | Taleb, Omar Maammar, Mohammed Klein, Christian Maitre, Michel Mensah-Nyagan, Ayikoe Guy |
author_facet | Taleb, Omar Maammar, Mohammed Klein, Christian Maitre, Michel Mensah-Nyagan, Ayikoe Guy |
author_sort | Taleb, Omar |
collection | PubMed |
description | Xanthurenic acid (XA) is a metabolite of the kynurenine pathway (KP) synthetized in the brain from dietary or microbial tryptophan that crosses the blood-brain barrier through carrier-mediated transport. XA and kynurenic acid (KYNA) are two structurally related compounds of KP occurring at micromolar concentrations in the CNS and suspected to modulate some pathophysiological mechanisms of neuropsychiatric and/or neurodegenerative diseases. Particularly, various data including XA cerebral distribution (from 1 µM in olfactory bulbs and cerebellum to 0.1–0.4 µM in A(9) and A(10)), its release, and interactions with G protein-dependent XA-receptor, glutamate transporter and metabotropic receptors, strongly support a signaling and/or neuromodulatory role for XA. However, while the parent molecule KYNA is considered as potentially involved in neuropsychiatric disorders because of its inhibitory action on dopamine release in the striatum, the effect of XA on brain dopaminergic activity remains unknown. Here, we demonstrate that acute local/microdialysis-infusions of XA dose-dependently stimulate dopamine release in the rat prefrontal cortex (four-fold increase in the presence of 20 µM XA). This stimulatory effect is blocked by XA-receptor antagonist NCS-486. Interestingly, our results show that the peripheral/intraperitoneal administration of XA, which has been proven to enhance intra-cerebral XA concentrations (about 200% increase after 50 mg/kg XA i.p), also induces a dose-dependent increase of dopamine release in the cortex and striatum. Furthermore, our in vivo electrophysiological studies reveal that the repeated/daily administrations of XA reduce by 43% the number of spontaneously firing dopaminergic neurons in the ventral tegmental area. In the substantia nigra, XA treatment does not change the number of firing neurons. Altogether, our results suggest that XA may contribute together with KYNA to generate a KYNA/XA ratio that may crucially determine the brain normal dopaminergic activity. Imbalance of this ratio may result in dopaminergic dysfunctions related to several brain disorders, including psychotic diseases and drug dependence. |
format | Online Article Text |
id | pubmed-8268472 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82684722021-07-10 A Role for Xanthurenic Acid in the Control of Brain Dopaminergic Activity Taleb, Omar Maammar, Mohammed Klein, Christian Maitre, Michel Mensah-Nyagan, Ayikoe Guy Int J Mol Sci Article Xanthurenic acid (XA) is a metabolite of the kynurenine pathway (KP) synthetized in the brain from dietary or microbial tryptophan that crosses the blood-brain barrier through carrier-mediated transport. XA and kynurenic acid (KYNA) are two structurally related compounds of KP occurring at micromolar concentrations in the CNS and suspected to modulate some pathophysiological mechanisms of neuropsychiatric and/or neurodegenerative diseases. Particularly, various data including XA cerebral distribution (from 1 µM in olfactory bulbs and cerebellum to 0.1–0.4 µM in A(9) and A(10)), its release, and interactions with G protein-dependent XA-receptor, glutamate transporter and metabotropic receptors, strongly support a signaling and/or neuromodulatory role for XA. However, while the parent molecule KYNA is considered as potentially involved in neuropsychiatric disorders because of its inhibitory action on dopamine release in the striatum, the effect of XA on brain dopaminergic activity remains unknown. Here, we demonstrate that acute local/microdialysis-infusions of XA dose-dependently stimulate dopamine release in the rat prefrontal cortex (four-fold increase in the presence of 20 µM XA). This stimulatory effect is blocked by XA-receptor antagonist NCS-486. Interestingly, our results show that the peripheral/intraperitoneal administration of XA, which has been proven to enhance intra-cerebral XA concentrations (about 200% increase after 50 mg/kg XA i.p), also induces a dose-dependent increase of dopamine release in the cortex and striatum. Furthermore, our in vivo electrophysiological studies reveal that the repeated/daily administrations of XA reduce by 43% the number of spontaneously firing dopaminergic neurons in the ventral tegmental area. In the substantia nigra, XA treatment does not change the number of firing neurons. Altogether, our results suggest that XA may contribute together with KYNA to generate a KYNA/XA ratio that may crucially determine the brain normal dopaminergic activity. Imbalance of this ratio may result in dopaminergic dysfunctions related to several brain disorders, including psychotic diseases and drug dependence. MDPI 2021-06-28 /pmc/articles/PMC8268472/ /pubmed/34203531 http://dx.doi.org/10.3390/ijms22136974 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Taleb, Omar Maammar, Mohammed Klein, Christian Maitre, Michel Mensah-Nyagan, Ayikoe Guy A Role for Xanthurenic Acid in the Control of Brain Dopaminergic Activity |
title | A Role for Xanthurenic Acid in the Control of Brain Dopaminergic Activity |
title_full | A Role for Xanthurenic Acid in the Control of Brain Dopaminergic Activity |
title_fullStr | A Role for Xanthurenic Acid in the Control of Brain Dopaminergic Activity |
title_full_unstemmed | A Role for Xanthurenic Acid in the Control of Brain Dopaminergic Activity |
title_short | A Role for Xanthurenic Acid in the Control of Brain Dopaminergic Activity |
title_sort | role for xanthurenic acid in the control of brain dopaminergic activity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268472/ https://www.ncbi.nlm.nih.gov/pubmed/34203531 http://dx.doi.org/10.3390/ijms22136974 |
work_keys_str_mv | AT talebomar aroleforxanthurenicacidinthecontrolofbraindopaminergicactivity AT maammarmohammed aroleforxanthurenicacidinthecontrolofbraindopaminergicactivity AT kleinchristian aroleforxanthurenicacidinthecontrolofbraindopaminergicactivity AT maitremichel aroleforxanthurenicacidinthecontrolofbraindopaminergicactivity AT mensahnyaganayikoeguy aroleforxanthurenicacidinthecontrolofbraindopaminergicactivity AT talebomar roleforxanthurenicacidinthecontrolofbraindopaminergicactivity AT maammarmohammed roleforxanthurenicacidinthecontrolofbraindopaminergicactivity AT kleinchristian roleforxanthurenicacidinthecontrolofbraindopaminergicactivity AT maitremichel roleforxanthurenicacidinthecontrolofbraindopaminergicactivity AT mensahnyaganayikoeguy roleforxanthurenicacidinthecontrolofbraindopaminergicactivity |